Five-year follow up of prostate adenocarcinoma patients treated with interstitial high dose rate brachytherapy monotherapy, a single-center experience.
- Author:
Soronio Kim Anthony
;
Tangco Caissa Elvira
;
Morales Marcelino L.
;
Magsanoc Juan Martin
;
Lantin-Penano Frances Lily
;
Tanseco Patrick Vincent
- Publication Type:Journal Article
- Keywords: PROSTATE ADENOCARCINOMA BRACHYTHERAPY
- MeSH: Human; Male; Aged; Middle Aged; Brachytherapy; Adenocarcinoma; Prostate
- From: Philippine Journal of Urology 2015;25(1):7-13
- CountryPhilippines
- Language:English
-
Abstract:
OBJECTIVE: Prostate cancer is the most common cancer in men and localized prostate adenocarcinoma has multiple treatment options. In this study, the objective was to review the outcome of patients that were treated with HDR brachytherapy as monotherapy in all prostate adenocarcinoma patients at the St Luke's Medical Center.
MATERIALS AND METHODS: Thirty three (33) patients who underwent HDR prostate brachytherapy as monotherapy for prostate adenocarcinoma in a single institution for the past 5 years received 38 Gy in 4 fractions. The charts of these patients were reviewed to determine biochemical control using the Phoenix criteria and ASTRO definition, and toxicity.
RESULTS: Patients showed good biochemical control, with 92.16% meeting the target PSA value of 2 ng/mL or less and a 96.51% without consecutive rise of PSA post brachytherapy. There was also minimal toxicity, with no report of gastrointestinal toxicity and 9.1% rate of temporary genitourinary toxicity.
CONCLUSION: Good biochemical control of prostate adenocarcinoma was achieved with the use of HDR brachytherapy as monotherapy, with a minimal toxicity profile.